These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Value of Clodronate in the treatment of bone metastasis]. Pouillart P, Beuzeboc P. Bull Cancer; 1991; 78(8):737-41. PubMed ID: 1834287 [Abstract] [Full Text] [Related]
23. Use of dichloromethylene diphosphonate in metastatic bone disease. Jung A, van Ouwenaller C, Chantraine A, Donath A, Rosini S. N Engl J Med; 1981 Aug 06; 305(6):343-4. PubMed ID: 6454076 [No Abstract] [Full Text] [Related]
25. Bisphosphonates in the treatment of malignant bone disease. Berenson JR, Lipton A. Annu Rev Med; 1999 Aug 06; 50():237-48. PubMed ID: 10073275 [Abstract] [Full Text] [Related]
26. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE. J Clin Oncol; 1997 Jan 06; 15(1):131-8. PubMed ID: 8996134 [Abstract] [Full Text] [Related]
28. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD. N Engl J Med; 1996 Feb 22; 334(8):488-93. PubMed ID: 8559201 [Abstract] [Full Text] [Related]
30. [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate]. Tubiana-Hulin M, de Vernejoul MC, Brière M, Miravet L, Clavel B. Presse Med; 1984 Feb 25; 13(8):483-6. PubMed ID: 6230630 [Abstract] [Full Text] [Related]
34. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Douglas DL, Duckworth T, Russell RG, Kanis JA, Preston CJ, Preston FE, Prenton MA, Woodhead JS. Lancet; 1980 May 17; 1(8177):1043-7. PubMed ID: 6103389 [Abstract] [Full Text] [Related]
35. Oral bisphosphonates: A review of clinical use in patients with bone metastases. Major PP, Lipton A, Berenson J, Hortobagyi G. Cancer; 2000 Jan 01; 88(1):6-14. PubMed ID: 10618600 [Abstract] [Full Text] [Related]
36. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Purohit OP, Radstone CR, Anthony C, Kanis JA, Coleman RE. Br J Cancer; 1995 Nov 01; 72(5):1289-93. PubMed ID: 7577484 [Abstract] [Full Text] [Related]
37. Use of bisphosphonates in cancer patients. Body JJ, Coleman RE, Piccart M. Cancer Treat Rev; 1996 Jul 01; 22(4):265-87. PubMed ID: 9025784 [No Abstract] [Full Text] [Related]
38. Parenteral diphosphonates for treating malignant hypercalcemia. Jung A, van Ouwenaller C, Chantraine A, Courvoisier B. Cancer; 1981 Oct 15; 48(8):1922-5. PubMed ID: 6456809 [Abstract] [Full Text] [Related]
39. Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. Merlini G, Parrinello GA, Piccinini L, Crema F, Fiorentini ML, Riccardi A, Pavesi F, Novazzi F, Silingardi V, Ascari E. Hematol Oncol; 1990 Oct 15; 8(1):23-30. PubMed ID: 2137106 [Abstract] [Full Text] [Related]
40. New diphosphonates to block bone resorption. Raisz LG. N Engl J Med; 1980 Feb 07; 302(6):347-8. PubMed ID: 6444242 [No Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]